Advertisement

Topics

Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017

01:00 EST 23 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Strong operating performance exceeds guidance with Group sales up 11.8%1 driven by Specialty Care and Core Operating Margin improvement despite Cabometyx® launch investments Acquisition of O...

Other Sources for this Article

Ipsen
Media
Didier Véron, +33 (0)1 58 33 51 16
Senior Vice-President, Public Affairs and Communication
didier.veron@ipsen.com
or
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Corporate External Communication Manager
brigitte.le.guennec@ipsen.com
or
Financial Community
Eugenia Litz, +44 (0) 1753 627721
Vice-President, Investor Relations
eugenia.litz@ipsen.com
or
Côme de La Tour du Pin, +33 (0)1 58 33 53 31
Investor Relations Manager
come.de.la.tour.du.pin@ipsen.com

NEXT ARTICLE

More From BioPortfolio on "Ipsen Delivers Strong 2016 Results and Expects Further Sales Growth and Margin Enhancement for 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...